key: cord-0912916-8ceabd6e authors: Yang, Yang; Shen, Chenguang; Li, Jinxiu; Yuan, Jing; Wei, Jinli; Huang, Fengmin; Wang, Fuxiang; Li, Guobao; Li, Yanjie; Xing, Li; Peng, Ling; Yang, Minghui; Cao, Mengli; Zheng, Haixia; Wu, Weibo; Zou, Rongrong; Li, Delin; Xu, Zhixiang; Wang, Haiyan; Zhang, Mingxia; Zhang, Zheng; Gao, George F.; Jiang, Chengyu; Liu, Lei; Liu, Yingxia title: Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 date: 2020-04-29 journal: J Allergy Clin Immunol DOI: 10.1016/j.jaci.2020.04.027 sha: 6682eebe7f583cf4885bec78924cfa36e826d1ff doc_id: 912916 cord_uid: 8ceabd6e Abstract Background The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. Objective To identify biomarkers for disease severity and progression of COVID-19. Methods Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe and 14 moderate patients were measured and analyzed in combination with clinical data. Results Fourteen cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IP-10, MCP-3, HGF, MIG and MIP-1α, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the five cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IP-10 and MCP-3 were excellent predictors for the progression of COVID-19, and the combination of the two cytokines showed the biggest area under the curve (AUC) of the receiver-operating characteristics (ROC) calculations with a value of 0.99. Conclusion In this study, we report biomarkers that highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, and provide potential therapeutic targets and strategies. ). The percentage of lymphocyte (LYM) as well as the CD4 and CD8 counts were 176 significantly lower in the critically ill and severe patients, while percentage of and neutrophil (NEU) 177 was higher in critically ill patients. Indexes for the evaluation of liver, kidney and heart injuries showed 178 no differences among the three groups upon admission (Table S1 ). Genetic Recombination, and 312 Pathogenesis of Coronaviruses Pathogenic human coronavirus infections: causes and 314 consequences of cytokine storm and immunopathology A Novel Coronavirus from Patients with 317 Pneumonia in China Genome Identified in a Cluster of Pneumonia Cases -Wuhan Daily briefing on novel coronavirus cases in China Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical Characteristics of Coronavirus 328 Disease 2019 in China Targeting the "cytokine storm" for 330 therapeutic benefit Acute Respiratory Distress Syndrome A(H7N9) virus results in 333 early induction of proinflammatory cytokine responses in both human lung epithelial and 334 endothelial cells and shows increased human adaptation compared with avian H5N1 virus Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes Biological features of novel avian influenza 340 A (H7N9) virus Comparison between human infections caused 342 by highly and low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and 343 virological findings Clinical and immunological characteristics 345 of human infections with H5N6 avian influenza virus Influenza virus-cytokine-protease 347 cycle in the pathogenesis of vascular hyperpermeability in severe influenza Characterization of cytokine/chemokine 350 profiles of severe acute respiratory syndrome An interferon-gamma-related cytokine 352 storm in SARS patients Analysis of serum cytokines in patients with 354 severe acute respiratory syndrome Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory 358 syndrome Middle East Respiratory Syndrome Coronavirus 360 (MERS-CoV): Infection, Immunological Response, and Vaccine Development MERS-CoV infection in 363 humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile Distinct immune response in 366 two MERS-CoV-infected patients: can we go from bench to bedside? Clinical features of patients infected with 369 2019 novel coronavirus in Wuhan, China 2019-novel coronavirus (2019-nCoV) 371 infections trigger an exaggerated cytokine response aggravating lung injury An expanded definition of the adult respiratory 373 distress syndrome Angiotensin II plasma levels are linked to 375 disease severity and predict fatal outcomes in H7N9-infected patients The Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The Epidemiological 378 Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) -China Clinical and biochemical indexes from 381 2019-nCoV infected patients linked to viral loads and lung injury of Novel Coronavirus-Infected Pneumonia Clinical features of patients infected with 385 2019 novel coronavirus in Wuhan, China A familial cluster of pneumonia associated 387 with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family 388 cluster T cell-mediated immune response to respiratory 390 coronaviruses Significant changes of peripheral T lymphocyte 392 subsets in patients with severe acute respiratory syndrome Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East 395 respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Cellular immune 398 responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in 399 senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection Recovery from 402 the Middle East respiratory syndrome is associated with antibody and T-cell responses New fronts emerge in the influenza cytokine storm Antiinflammatory action of glucocorticoids--new mechanisms for old 407 drugs Adjuvant Corticosteroid Treatment in 409 Adults With Influenza A (H7N9) Viral Pneumonia On the use of corticosteroids for 2019-nCoV pneumonia Re-emergence of fatal 413 human influenza A subtype H5N1 disease Fatal outcome of 415 human influenza A (H5N1) is associated with high viral load and hypercytokinemia CXCL10-CXCR3 enhances the 418 development of neutrophil-mediated fulminant lung injury of viral and nonviral origin Monoclonal antibody against 421 CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury † Values shown represent the mean and inter-quartile range (IQR)